Mounjaro is the brand name for tirzepatide, a prescription medicine that acts on two hormone pathways involved in blood-sugar regulation and appetite: GIP and GLP-1. In the European Union, it is authorised for type 2 diabetes and, for eligible adults, weight management alongside a reduced-calorie diet and increased physical activity. It is not the same compound as retatrutide, and it is not an over-the-counter “research peptide.”
The useful question is not whether one injection is “strong.” It is whether a licensed clinician thinks the medicine fits a person’s health, goals, history and ability to follow up over time.
What is Mounjaro?
Mounjaro is a brand of tirzepatide. Tirzepatide is a peptide medicine engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These signalling pathways influence glucose control and appetite. The medicine can slow stomach emptying, particularly early in treatment, and may help people feel full sooner or for longer.
That mechanism helps explain why tirzepatide can affect both blood glucose and body weight. It does not mean the medicine “resets” metabolism, removes the underlying causes of weight gain, or produces the same response in every person.
Is Mounjaro approved for weight management in Europe?
Yes. The European Medicines Agency lists Mounjaro as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of at least 30, or a BMI of at least 27 with at least one weight-related health condition. It is also authorised for type 2 diabetes under the terms in its product information. Mounjaro is prescription-only. Local availability, reimbursement and the exact product information should be checked in the country where care is provided.
Approval is not a recommendation for everyone who wants to lose a few kilograms. A clinician should consider the person’s medical history, other medicines, symptoms, treatment goals and the risks of weight change. The medicine should not be sourced from social-media sellers or sold as an unregulated “research” product.
What did the weight-management trials find?
In the phase 3 SURMOUNT-1 trial, 2,539 adults with obesity, or overweight plus a weight-related complication, took tirzepatide or placebo for 72 weeks alongside lifestyle support. Participants did not have type 2 diabetes. In the trial’s treatment-regimen analysis, average body-weight change was about −15.0%, −19.5% and −20.9% with the three studied tirzepatide doses, compared with −3.1% with placebo.
Those are group averages from a controlled study, not a forecast for an individual. People differed in their response, side effects and ability to stay in the trial. The study was funded by the manufacturer, which is relevant context when interpreting any medicine trial; the findings are still a published randomised phase 3 comparison.
Weight management is often a longer conversation than “how quickly can I lose weight?” In SURMOUNT-4, participants first received open-label tirzepatide for 36 weeks. Those who then switched to placebo regained weight on average during the following year, while those who continued treatment lost additional weight. The study supports planning for maintenance and follow-up; it does not establish what any one person should do or how their care should change.
What are the main risks and limitations?
The most common side effects are gastrointestinal: nausea, diarrhoea, vomiting, abdominal discomfort and constipation. These effects were reported more often during dose escalation in clinical studies. They can contribute to dehydration, especially if vomiting or diarrhoea is persistent.
The EU product information also warns about acute pancreatitis and advises caution in people with a history of pancreatitis. Gallstones and gallbladder inflammation have been reported. Low blood sugar is more relevant when tirzepatide is used with insulin or a sulphonylurea. Because the medicine delays stomach emptying, people should tell their clinical and anaesthesia teams before planned procedures involving general anaesthesia or deep sedation. This is not a complete safety list; the current patient leaflet and a prescriber are the right sources for an individual’s situation.
Tirzepatide is not recommended during pregnancy. The EMA product information says it should be stopped at least one month before a planned pregnancy. Anyone who is pregnant, planning pregnancy, breastfeeding or using oral medicines that need careful monitoring should discuss this with a clinician before treatment decisions are made.
What happens if treatment stops?
Weight regain can happen after treatment is withdrawn. In SURMOUNT-4, participants switched to placebo after the initial treatment period regained an average of about 14% of their body weight during the 52-week withdrawal period, whereas those continuing tirzepatide maintained and extended their reduction. The trial involved a selected group who had already completed a 36-week treatment phase; it should not be read as a guaranteed outcome for every patient.
This is why a sound treatment conversation includes affordability, duration, side effects, nutrition, strength and follow-up—not only the initial target on the scale. Do not stop or change a prescribed medicine without discussing it with the prescriber.
Questions worth taking to a clinician
- What health goal are we treating, and how will we measure whether treatment is helping?
- How do my medical history and current medicines affect the benefits and risks?
- What symptoms should prompt me to call the clinic urgently?
- How will nutrition, hydration and resistance exercise be supported while weight changes?
- What is the plan for reassessment, ongoing costs and possible treatment interruption?
Mounjaro, semaglutide and retatrutide are not interchangeable
Tirzepatide (Mounjaro) targets GIP and GLP-1 receptors. Semaglutide acts on GLP-1 receptors and is sold under different brand names for different indications. Retatrutide targets GIP, GLP-1 and glucagon receptors and remains investigational as of this article’s evidence update. Their trial results come from different populations and study designs, so comparing headline percentages across separate trials can be misleading.
For a deeper look at another compound, read our retatrutide Phase 3 evidence update. For an overview of what peptide research can and cannot tell us, see What Are Peptides? Our at-home testing guide explains why a lab panel cannot replace an appropriate clinical assessment.
Editorial boundary: Immortal Pills provides educational content and does not prescribe, sell or source tirzepatide. Treatment decisions belong with a licensed healthcare professional who knows the person’s health history. This guide was checked against the sources below on 15 October 2026; it has not been presented as clinician-reviewed.
Sources
- European Medicines Agency. Mounjaro: EPAR and current EU product information (product information last updated 21 September 2026; accessed 15 October 2026).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205–216. doi:10.1056/NEJMoa2206038.
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: SURMOUNT-4. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945.
Turn this into a habit in 30 days
The 30-Day Longevity Reset turns the research into 15 minutes a day: eating window, movement, strength and calm – one simple step at a time. Join the waitlist for first access and a founding-member price.
